Linagliptin-Role in the Reversal of Aβ-Mediated Impairment of Insulin Signaling and Reduced Neurotoxicity in AD Pathogenesis: Some Considerations.
作者信息
Srinivas Nuggehally R
机构信息
Suramus Bio, Bangalore, India.
出版信息
CNS Neurosci Ther. 2015 Dec;21(12):962-3. doi: 10.1111/cns.12475. Epub 2015 Nov 7.
Abstract
摘要
相似文献
1
Linagliptin-Role in the Reversal of Aβ-Mediated Impairment of Insulin Signaling and Reduced Neurotoxicity in AD Pathogenesis: Some Considerations.利那格列汀在逆转Aβ介导的胰岛素信号损伤及降低AD发病机制中的神经毒性方面的作用：一些思考
CNS Neurosci Ther. 2015 Dec;21(12):962-3. doi: 10.1111/cns.12475. Epub 2015 Nov 7.
2
DPP-4 Inhibitor Linagliptin Attenuates Aβ-induced Cytotoxicity through Activation of AMPK in Neuronal Cells.二肽基肽酶-4抑制剂利那格列汀通过激活神经元细胞中的AMPK减轻Aβ诱导的细胞毒性。
CNS Neurosci Ther. 2015 Jul;21(7):549-57. doi: 10.1111/cns.12404. Epub 2015 May 26.
3
Linagliptin, a DPP-4 inhibitor, ameliorates Aβ (1-42) peptides induced neurodegeneration and brain insulin resistance (BIR) via insulin receptor substrate-1 (IRS-1) in rat model of Alzheimer's disease.利拉利汀，一种 DPP-4 抑制剂，通过胰岛素受体底物-1（IRS-1）改善阿尔茨海默病大鼠模型中的 Aβ（1-42）肽诱导的神经退行性变和大脑胰岛素抵抗（BIR）。
Neuropharmacology. 2021 Sep 1;195:108662. doi: 10.1016/j.neuropharm.2021.108662. Epub 2021 Jun 11.
4
Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer's Disease.利拉利汀，一种二肽基肽酶-4 抑制剂，可减轻阿尔茨海默病 3xTg-AD 小鼠模型的认知缺陷和病理。
Mol Neurobiol. 2017 Oct;54(8):6074-6084. doi: 10.1007/s12035-016-0125-7. Epub 2016 Oct 3.
5
The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway.DPP-4 抑制通过 SDF-1α/CXCR4 途径改善中风后的功能结局。
Cardiovasc Diabetol. 2018 May 19;17(1):60. doi: 10.1186/s12933-018-0702-3.
6
Differential Effects of Linagliptin on the Function of Human Islets Isolated from Non-diabetic and Diabetic Donors.利拉鲁肽对来源于非糖尿病和糖尿病供者的人胰岛功能的差异影响。
Sci Rep. 2017 Aug 11;7(1):7964. doi: 10.1038/s41598-017-08271-9.
7
Population Pharmacokinetic/Pharmacodynamic Modelling of Dipeptidyl Peptidase IV Inhibitors.二肽基肽酶IV抑制剂的群体药代动力学/药效学建模
Clin Pharmacokinet. 2015 Jul;54(7):673-5. doi: 10.1007/s40262-015-0279-x.
8
The DPP4 Inhibitor Linagliptin Protects from Experimental Diabetic Retinopathy.二肽基肽酶4抑制剂利格列汀可预防实验性糖尿病视网膜病变。
PLoS One. 2016 Dec 12;11(12):e0167853. doi: 10.1371/journal.pone.0167853. eCollection 2016.
9
Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.利格列汀治疗2型糖尿病：药物安全性评估。
Expert Opin Drug Saf. 2015 Jan;14(1):149-59. doi: 10.1517/14740338.2014.971008. Epub 2014 Oct 29.
10
Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.利拉利汀，一种开发用于治疗 2 型糖尿病的二肽基肽酶-4 抑制剂：在健康成年日本男性受试者中进行的单次和多次递增剂量、随机、双盲、安慰剂对照的 I 期临床试验。
Clin Ther. 2010 Jun;32(6):1188-204. doi: 10.1016/j.clinthera.2010.06.004.
引用本文的文献
1
Exploring the Anxiolytic Potential of NPY by a Dipeptidyl Peptidase-IV Inhibitor in an Animal Model of PTSD.在创伤后应激障碍动物模型中通过二肽基肽酶-IV抑制剂探索神经肽Y的抗焦虑潜力
Int J Neuropsychopharmacol. 2024 Dec 1;27(12). doi: 10.1093/ijnp/pyae062.
2
Comparing major and mild cognitive impairment risks in older type-2 diabetic patients: a Danish register-based study on dipeptidyl peptidase-4 inhibitors vs. glucagon-like peptide-1 analogues.比较老年 2 型糖尿病患者中主要和轻度认知障碍风险：丹麦基于登记的研究比较二肽基肽酶-4 抑制剂与胰高血糖素样肽-1 类似物。
J Neurol. 2024 Jun;271(6):3417-3425. doi: 10.1007/s00415-024-12300-9. Epub 2024 Mar 22.
3
Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents.将二肽基肽酶-4抑制剂和胰高血糖素样肽-1激动剂重新定位为潜在的神经保护剂。
Neural Regen Res. 2019 May;14(5):745-748. doi: 10.4103/1673-5374.249217.
4
Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent.将 Omarigliptin 重新定位为每周一次的鼻内抗帕金森病药物。
Sci Rep. 2018 Jun 12;8(1):8959. doi: 10.1038/s41598-018-27395-0.
本文引用的文献
1
Retrospective and Prospective Human Intravenous and Oral Pharmacokinetic Projection of Dipeptidyl peptidase-IV Inhibitors Using Simple Allometric Principles - Case Studies of ABT-279, ABT-341, Alogliptin, Carmegliptin, Sitagliptin and Vildagliptin.利用简单的异速生长原理对二肽基肽酶-IV抑制剂进行回顾性和前瞻性人体静脉内及口服药代动力学预测——阿必鲁肽、ABT-341、阿格列汀、卡格列汀、西他列汀和维格列汀的案例研究
J Pharm Pharm Sci. 2015;18(3):434-48. doi: 10.18433/j3tk55.
2
DPP-4 Inhibitor Linagliptin Attenuates Aβ-induced Cytotoxicity through Activation of AMPK in Neuronal Cells.二肽基肽酶-4抑制剂利那格列汀通过激活神经元细胞中的AMPK减轻Aβ诱导的细胞毒性。
CNS Neurosci Ther. 2015 Jul;21(7):549-57. doi: 10.1111/cns.12404. Epub 2015 May 26.
3
Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease.维达列汀：一种抗糖尿病药物，可改善链脲佐菌素诱导的阿尔茨海默病模型中的认知功能障碍和病理改变。
J Pharm Pharmacol. 2013 Dec;65(12):1773-84. doi: 10.1111/jphp.12148. Epub 2013 Oct 10.
4
Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease.沙格列汀：二肽基肽酶-4 抑制剂改善链脲佐菌素诱导的阿尔茨海默病。
Neuropharmacology. 2013 Sep;72:291-300. doi: 10.1016/j.neuropharm.2013.04.008. Epub 2013 Apr 17.
5
Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods.采用体外细胞培养方法评价和预测利拉利汀的潜在药物-药物相互作用。
Drug Metab Dispos. 2013 Jan;41(1):149-58. doi: 10.1124/dmd.112.048470. Epub 2012 Oct 16.
6
Linagliptin: a review of its use in the management of type 2 diabetes mellitus.利拉鲁肽：在 2 型糖尿病管理中的应用评价。
Drugs. 2012 Sep 10;72(13):1793-824. doi: 10.2165/11209570-000000000-00000.
7
Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.二肽基肽酶-4 抑制剂的临床药代动力学比较。
Clin Pharmacokinet. 2012 Aug 1;51(8):501-14. doi: 10.1007/BF03261927.
8
Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain.新型 GLP-1 拟肽被开发用于治疗 2 型糖尿病，可促进大脑祖细胞增殖。
J Neurosci Res. 2011 Apr;89(4):481-9. doi: 10.1002/jnr.22565. Epub 2011 Jan 10.
9
Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.β-淀粉样肽通过血脑屏障的清除：对阿尔茨海默病治疗的意义。
CNS Neurol Disord Drug Targets. 2009 Mar;8(1):16-30. doi: 10.2174/187152709787601867.
10
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.肠促胰岛素系统：2型糖尿病中的胰高血糖素样肽-1受体激动剂和二肽基肽酶-4抑制剂
Lancet. 2006 Nov 11;368(9548):1696-705. doi: 10.1016/S0140-6736(06)69705-5.
Zotero 插件